Synergistic interaction between MEK inhibitor and gefitinib in EGFR-TKI-resistant human lung cancer cells

With the increasing use of epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKIs) in patients with advanced non-small cell lung cancer (NSCLC), acquired resistance has become a major clinical problem. A combination of different signaling pathway inhibitors is a promising strategy to...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Oncol Lett
Hlavní autoři: LI, SUXIA, CHEN, SUXIU, JIANG, YIYAN, LIU, JIEFAN, YANG, XIAOLEI, QUAN, SHICHAO
Médium: Artigo
Jazyk:Inglês
Vydáno: D.A. Spandidos 2015
Témata:
Articles
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC4580034/
https://ncbi.nlm.nih.gov/pubmed/26622906
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3892/ol.2015.3577
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky